Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.

Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.

Find the latest Sage Therapeutics, Inc. (SAGE) stock quote, history, news and other vital information to help you with your stock trading and investing.

CAMBRIDGE, Mass., January 12, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at ...

Nov 20, 2024 · Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare ...

Sage Therapeutics | 107,929 followers on LinkedIn. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. | Sage Therapeutics is a ...

Feb 6, 2023 · The Investor Relations website contains information about Sage Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted ...

Jan 27, 2025 · After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

6 days ago · Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.